Research & Innovation | National Cancer Centre Singapore

Research Cellular & Molecular Research The Division of Cellular & Molecular Research is focused on understanding the mechanistic basis of tumour development and treatment response; as well as the translation of bench-based findings to devise strategies to improve the early detection and treatment of cancers.

Research Medical Sciences The Division of Medical Sciences has evolved in the last decade to one that is completely focused on the mission of translating biological discoveries into the clinic.

Research Clinical Trials & Epidemiological Sciences The Division was conceived to provide support and to encourage clinical trials within NCCS.

Research Facilities

With almost 10,000 square metres of research space, NCCS houses advanced translational research facilities for scientists and clinician-scientists in Singapore.

Clinical Trials

At NCCS, clinical trials are led by a highly-trained multidisciplinary team of clinicians, researchers, nurses and support staff experienced in managing the protocol and delivery of local and international trials.

Our Researchers

Meet our researchers, driving innovation and uncovering groundbreaking discoveries every day.

Find a Researcher

Discover our expert researchers and their groundbreaking work in cancer, from bench to bedside, at NCCS.

Research Themes and Core Platforms

Explore our dynamic research programmes, actively pushing boundaries and sparking transformative solutions.

NCCS Research Reports

Dive into our insightful research reports, actively shaping knowledge and driving impactful discoveries.

NCCS Research Committee & Scientific Advisory Board

Research News

Research 本地人口健康研究完成收集10万人基因数据研究即将进入新阶段本地大规模人口健康研究SG100K已完成收集10万人健康与基因信息的工作，并且进入了基因组测序和分析阶段.

09 Nov 2025 | Lianhe Zaobao Read Story

Research New therapy shows promise in treating advanced HER2 mutated lung cancer A global, multicentre, phase 1/2 clinical trial that included clinician-scientists and researchers from MD Anderson Cancer Centre, Seoul National University and the National Cancer Centre Singapore has indicated positive results in treating advanced HER2-mutant non-small-cell lung cancer (NSCLC) with sevabertinib, an oral HER2-targeted tyrosine kinase inhibitor.

21 Oct 2025 Read Story

View All News